SIEGALL CLAY B

SEC source: 0001167496-26-000005 · form4-07272026_040701.xml · derivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2036-07-22

F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001167496-26-000005 · form4-07272026_040701.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 870,704

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001193125-26-267836 · ownership.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,608

F1 · kind: Represents shares of the Issuer's common stock purchased in connection with the Issuer's underwritten offering, which closed on June 11, 2026.

SEC source: 0001193125-26-254123 · ownership.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2036-05-29

F1 · derivative.exercise_date: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001193125-26-240347 · ownership.xml · derivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 128,054 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

SEC source: 0001193125-26-240347 · ownership.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,108

SEC source: 0001167496-26-000003 · form4-03312026_110335.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 690,704

F1 · price: The weighted average purchase price for the transaction report was $19.67, and the range of prices were between $19.63 and $19.70, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001167496-25-000010 · form4-12302025_111219.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 665,254

SEC source: 0001167496-25-000008 · form4-12222025_121251.xml · nonDerivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 660,525

F2 · kind: The Reporting Person gifted the shares of the Issuer's common stock to the Clay B. Siegall 2025 Grantor Retained Annuity Trust, of which the Reporting Person's brother is the trustee and the Reporting Person's children are the beneficiaries. The Reporting Person does not have or share investment control over these shares.

F3 · shares: The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025 (the "Lock-Up Agreement"). The transferee has agreed to be bound by the terms of the Lock-Up Agreement.

SEC source: 0001167496-25-000008 · form4-12222025_121251.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 860,525

F1 · price: The weighted average purchase price for the transaction report was $20.48, and the range of prices were between $20.36 and $20.50, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001167496-25-000006 · form4-12182025_101250.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 853,247

F1 · kind: The Reporting Person purchased the shares in connection with the Issuer's recently completed underwritten public offering of common stock.

SEC source: 0001167496-25-000005 · form4-10282025_061021.xml · derivative · entry 3

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,800 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F2 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

SEC source: 0001167496-25-000005 · form4-10282025_061021.xml · derivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F2 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

SEC source: 0001167496-25-000005 · form4-10282025_061021.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F2 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

SEC source: 0001193125-25-189085 · ownership.xml · derivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,054

Underlying: Common Stock · 128,054 shares

Expires not disclosed

F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

SEC source: 0001193125-25-189085 · ownership.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,054

F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

SEC source: 0001415889-25-020782 · form4-07312025_100706.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2035-07-28

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0000950170-25-096284 · ownership.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,150

Underlying: Common Stock · 33,150 shares

Expires 2035-07-14

F1 · derivative.exercise_date: This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001827506-25-000078 · wk-form4_1749242015.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2035-06-04

F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001415889-25-009017 · form4-03262025_080357.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 806,736

F1 · price: The weighted average purchase price for the transaction report was $7.29, and the range of prices were between $7.16 and $7.40, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-002824 · form4-02042025_020240.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 669,636

F1 · kind: The Reporting Person purchased the shares in connection with the Issuer's recently completed underwritten public offering of common stock.

SEC source: 0001415889-24-027601 · form4-11252024_011157.xml · nonDerivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 519,636

F2 · price: The weighted average purchase price for the transaction report was $9.7787, and the range of prices were between $9.41 and $9.90. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-027601 · form4-11252024_011157.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 485,693

F1 · price: The weighted average purchase price for the transaction report was $9.5412, and the range of prices were between $9.41 and 9.68. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-021240 · form4-08132024_090811.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0000950170-24-076398 · ownership.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,700

Underlying: Common Stock · 27,700 shares

Expires 2034-06-21

F1 · derivative.exercise_date: This option represents the right to purchase a total of 27,700 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001827506-24-000056 · wk-form4_1717790594.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-04

F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001415889-24-013935 · form4-05212024_080525.xml · nonDerivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 419,636

F2 · price: The weighted average purchase price for the transaction report was $13.7784, and the range of prices were between $13.62 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-013935 · form4-05212024_080525.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,202

F1 · price: The weighted average purchase price for the transaction report was $13.907,and the range of prices were between $13.77 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0000950170-24-028808 · ownership.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,409

Underlying: Common Stock · 33,409 shares

Expires 2034-03-06

F1 · derivative.exercise_date: This option represents the right to purchase a total of 33,409 shares of the Issuer's common stock, and vests in three equal annual installments on each of the first three anniversaries of March 1, 2024, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001209191-23-058774 · doc4.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-12-12

F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable in thirty-six (36) equal monthly installments beginning on January 13, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC source: 0001209191-23-052053 · doc4.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 319,636

SEC source: 0001203311-22-000035 · edgardoc.xml · derivative · entry 6

SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,129

Underlying: Common Stock · 10,593 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0001203311-22-000035 · edgardoc.xml · derivative · entry 5

SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,722

Underlying: Common Stock · 6,450 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0001203311-22-000035 · edgardoc.xml · nonDerivative · entry 4

SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 666,060

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $125.00 to $125.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001203311-22-000035 · edgardoc.xml · nonDerivative · entry 3

SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 676,653

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001203311-22-000035 · edgardoc.xml · nonDerivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 666,060

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $126.00 to $126.55. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001203311-22-000035 · edgardoc.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 672,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001209191-22-027668 · doc4.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-05-04

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC source: 0001203311-22-000033 · edgardoc.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 666,060

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0000899243-22-014397 · doc4.xml · derivative · entry 21

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,172

Underlying: Common Stock · 474 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0000899243-22-014397 · doc4.xml · derivative · entry 20

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,646

Underlying: Common Stock · 1,900 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0000899243-22-014397 · doc4.xml · derivative · entry 19

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,546

Underlying: Common Stock · 3,828 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0000899243-22-014397 · doc4.xml · derivative · entry 18

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,374

Underlying: Common Stock · 2,400 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0000899243-22-014397 · doc4.xml · derivative · entry 17

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,774

Underlying: Common Stock · 4,692 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0000899243-22-014397 · doc4.xml · derivative · entry 16

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,466

Underlying: Common Stock · 2,100 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0000899243-22-014397 · doc4.xml · derivative · entry 15

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,566

Underlying: Common Stock · 1,649 shares

Expires 2022-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 14

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 667,945

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F9 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $157.17 to $157.28. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 13

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 668,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 12

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 667,945

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F8 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $156.15 to $157.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 11

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 669,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.